Suchergebnisse - "Arcaini, Luca"

PubPharm (245)

51

A prognostic model for patients with lymphoma and COVID-19 : a multicentre cohort study

enthalten in: Blood advances | 2022

von Visco, C. | Marcheselli, L. | Mina, R. | +55

ErratumIn: Blood Adv. 2023 Mar 28;7(6):1065. - PMID 36943316

52

Case Report : A rare case of small bowel obstruction secondary to plasma cell myeloma

enthalten in: Frontiers in oncology | 2022

von Bonometti, A. | Aronico, N. | Santacroce, G. | +8

53

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma : Results from an Italian Phase IIIb Study

enthalten in: Advances in hematology | 2022

von Petrini, M. | Gaidano, G. | Mengarelli, A. | +30

54

Muscle weakness as an additional criterion for grading sarcopenia-related prognosis in patients with cancer

enthalten in: Cancer medicine | 2022

von Cereda, E. | Tancredi, R. | Klersy, C. | +13

55

Sequential next generation sequencing analysis in homogeneously treated low risk NPM1‐mutated acute myeloid leukemia with an adverse clinical outcome

enthalten in: American Journal of Hematology | 2022

von Rossi, M. | Nizzoli, M. | Gallì, A. | +13

56

Isolated congenital asplenia : An overlooked cause of thrombocytosis

enthalten in: American Journal of Hematology | 2022

von Borsani, O. | Asano, T. | Boisson, B. | +10

57

Impact of severe acute respiratory syndrome coronavirus‐2 infection on the outcome of primary central nervous system lymphoma treatment : A study of the International PCNSL Collaborative Group

enthalten in: British Journal of Haematology | 2022

von Steffanoni, S. | Calimeri, T. | Laurenge, A. | +25

58

Muscle weakness as an additional criterion for grading sarcopenia‐related prognosis in patients with cancer

enthalten in: Cancer Medicine | 2022

von Cereda, E. | Tancredi, R. | Klersy, C. | +13

59

B‐cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non‐Hodgkin's Lymphoma

enthalten in: Hematological Oncology | 2022

von Gragnani, L. | Lorini, S. | Marri, S. | +9

60

Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma : Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study)

enthalten in: Hematological Oncology | 2022

von Rigacci, L. | Battistini, R. | Kovalchuk, S. | +16